As of 2025-07-14, the Relative Valuation of Summit Therapeutics Inc (SMMT) is (3.33) USD. This relative valuation is based on P/E multiples. With the latest stock price at 25.00 USD, the upside of Summit Therapeutics Inc based on Relative Valuation is -113.3%.
The range of the Relative Valuation is (2.53) - (4.52) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 9.0x - 18.9x | 13.6x |
| Forward P/E multiples | 10.6x - 21.5x | 14.2x |
| Fair Price | (2.53) - (4.52) | (3.33) |
| Upside | -110.1% - -118.1% | -113.3% |
| Date | P/E |
| 2025-07-11 | -107.24 |
| 2025-07-10 | -108.08 |
| 2025-07-09 | -103.31 |
| 2025-07-08 | -96.01 |
| 2025-07-07 | -94.42 |
| 2025-07-03 | -102.52 |
| 2025-07-02 | -94.46 |
| 2025-07-01 | -88.53 |
| 2025-06-30 | -88.87 |
| 2025-06-27 | -86.03 |
| 2025-06-26 | -89.03 |
| 2025-06-25 | -88.82 |
| 2025-06-24 | -87.36 |
| 2025-06-23 | -85.15 |
| 2025-06-20 | -85.86 |
| 2025-06-18 | -84.19 |
| 2025-06-17 | -82.89 |
| 2025-06-16 | -83.31 |
| 2025-06-13 | -82.60 |
| 2025-06-12 | -84.19 |
| 2025-06-11 | -81.77 |
| 2025-06-10 | -92.21 |
| 2025-06-09 | -90.03 |
| 2025-06-06 | -85.98 |
| 2025-06-05 | -82.39 |
| 2025-06-04 | -81.68 |
| 2025-06-03 | -86.11 |
| 2025-06-02 | -74.02 |
| 2025-05-30 | -76.07 |
| 2025-05-29 | -109.45 |
| 2025-05-28 | -108.74 |
| 2025-05-27 | -107.07 |
| 2025-05-23 | -107.95 |
| 2025-05-22 | -107.62 |
| 2025-05-21 | -106.11 |
| 2025-05-20 | -101.85 |
| 2025-05-19 | -100.27 |
| 2025-05-16 | -99.68 |
| 2025-05-15 | -96.42 |
| 2025-05-14 | -95.00 |
| 2025-05-13 | -102.77 |
| 2025-05-12 | -105.49 |
| 2025-05-09 | -100.06 |
| 2025-05-08 | -102.94 |
| 2025-05-07 | -101.44 |
| 2025-05-06 | -101.06 |
| 2025-05-05 | -117.01 |
| 2025-05-02 | -116.51 |
| 2025-05-01 | -103.02 |
| 2025-04-30 | -100.73 |